| Literature DB >> 26417432 |
Samuel Antwi-Baffour1, Jonathan Adjei1, Claudia Aryeh1, Ransford Kyeremeh1, Foster Kyei2, Mahmood A Seidu1.
Abstract
Platelet-derived extracellular vesicles (PEVs) are described as sub-cellular vesicles released into circulation upon platelets shear stress, activation, injury, or apoptosis. They are considered as universal biomarkers in a wide range of physiological and pathological processes. They are of tremendous significance for the prediction, diagnosis, and observation of the therapeutic success of many diseases. Understanding their biosynthesis and therefore functional properties would contribute to a better understanding of the pathological mechanisms leading to various diseases in which their levels are raised and they are implicated. The review takes a critical look at the historical background of PEVs, their structural components, the mechanism of their formation, physiological, and exogenous stimuli inducing their release and their detection. It concludes by highlighting on the importance of undertaking in-depth studies into PEVs biosynthesis and subsequently gaining a better understanding of their biological role in general.Entities:
Keywords: Actin; biomarkers; centrifugation; extracellular vesicles; phosphatidylserine; phospholipids
Year: 2015 PMID: 26417432 PMCID: PMC4578515 DOI: 10.1002/iid3.66
Source DB: PubMed Journal: Immun Inflamm Dis ISSN: 2050-4527
A table with different proteins differentially enriched in platelets EVs in comparison to EVs from other cell types
| Proteins from platelet EVs | Proteins from EVs from other cell types |
|---|---|
| Platelet basic protein | 14-3-3 protein beta/alpha |
| Actin, cytoplasmic 1 | 14-3-3 protein gamma |
| CD9 antigen | Aminopeptidase N |
| Fibrinogen beta chain | Catenin alpha-1 |
| Haemoglobin subunit beta | Catenin beta-1 |
| 14-3-3 protein zeta/delta | CD151 antigen |
| Haemoglobin subunit | CD 9 antigen |
| Gamma-1 | CD97 antigen precursor |
| Integrin alpha-IIb | Claudin-1 |
| Integrin beta-3 | Claudin-3 |
| Platelet factor 4 | Crumbs homology 2 precursor |
| Platelet glycoprotein 1b beta chain | Dipeptidyl peptidase 4 |
| Ras-related protein Rap-1b | Galectin -3 |
| Thrombospondin-1 | Galectin-4 |
| Fibrinogen alpha chain | GTPase KRas precursor |
| Fibrinogen gamma chain | Junction plakoglobin |
| Tropomyosin alpha-4 chain | Lin-7 homolog C |
| Serum albumin | Macrophage migration inhibitory factor |
| Myosin light polypeptide 6 | Mucin-1 precursor |
| Multimerin-1 | Mucin-13 precursor |
| Beta-actin-lke protein 2 | Mucin-16 |
| Gelsolin | Peroxiredoxin-1 |
| Filamin-A | Phosphatidylethalomine-binding protein 1 |
| Profiling-1 | Plexin B2 |
| Platelet glycoprotein 1X | Protaglanding F2 receptor |
| Erythrocyte band 7 integral membrane protein | Ras-related protein R-Ras precursor |
| Myosin regulatory light chain 12A | Ras-related protein R-Ras2 precursor |
| Fermitin family homolog 3 | Tetraspanin-1 |
| Talin-1 | Transgelin-2 |
Figure 1A figure with the different phases depicting how PEVs are formed. (a) Representation of the resting cell: Scramblase is inactive while Translocase and Floppase are active maintaining membrane asymmetry. (b) Cell Activation: Scramblase, Calpain, and Gelsolin are activated due to calcium release from ER. Calpain cleaves long actin filaments. Gelsolin cleaves actin-capping proteins. Translocase is inactivated. Membrane asymmetry is compromised. (c) Cytoskeletal Disruption: protein anchorage to the cytoskeleton is disrupted allowing membrane budding. (d) Extracellular Vesicles (EVs) formation: EVs are formed and released with increased phosphatidylserine exposed on their external surface.